Arteris (NASDAQ:AIP – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at Rosenblatt Securities in a note issued to investors on Wednesday, Benzinga reports. They currently have a $15.00 target price on the stock. Rosenblatt Securities’ price target indicates a potential upside of 109.50% from the company’s current price.
Separately, Westpark Capital reiterated a “buy” rating and issued a $11.00 price target on shares of Arteris in a research note on Wednesday, July 31st.
View Our Latest Stock Report on Arteris
Arteris Trading Up 5.8 %
Insiders Place Their Bets
In other Arteris news, CEO K Charles Janac sold 5,520 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $7.18, for a total transaction of $39,633.60. Following the completion of the transaction, the chief executive officer now owns 287,247 shares of the company’s stock, valued at $2,062,433.46. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Paul L. Alpern sold 3,615 shares of the stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $7.13, for a total value of $25,774.95. Following the completion of the transaction, the vice president now owns 68,084 shares of the company’s stock, valued at approximately $485,438.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO K Charles Janac sold 5,520 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $7.18, for a total transaction of $39,633.60. Following the completion of the transaction, the chief executive officer now directly owns 287,247 shares of the company’s stock, valued at approximately $2,062,433.46. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 124,110 shares of company stock worth $902,044. Corporate insiders own 33.70% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. GSA Capital Partners LLP lifted its stake in Arteris by 26.9% in the first quarter. GSA Capital Partners LLP now owns 132,952 shares of the company’s stock worth $973,000 after purchasing an additional 28,165 shares during the last quarter. Vanguard Group Inc. lifted its stake in Arteris by 0.3% in the first quarter. Vanguard Group Inc. now owns 1,146,224 shares of the company’s stock worth $8,390,000 after purchasing an additional 3,242 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Arteris by 28.1% in the first quarter. Acadian Asset Management LLC now owns 534,472 shares of the company’s stock worth $3,911,000 after purchasing an additional 117,312 shares during the last quarter. Silvercrest Asset Management Group LLC lifted its stake in Arteris by 25.2% in the first quarter. Silvercrest Asset Management Group LLC now owns 711,903 shares of the company’s stock worth $5,211,000 after purchasing an additional 143,385 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Arteris in the second quarter worth about $580,000. Institutional investors own 64.36% of the company’s stock.
Arteris Company Profile
Arteris, Inc provides semiconductor interconnect intellectual property (IP) and System-on-Chip (Soc) Integration Automation software solutions (SIA) in the Americas, the Asia Pacific, Europe, and the Middle East. The company develops, licenses, and supports the on-chip interconnect fabric technology used in Soc designs and Network-on-Chip (NoC) interconnect IP.
See Also
- Five stocks we like better than Arteris
- What is a Bond Market Holiday? How to Invest and Trade
- 2 Alternative Internet Stocks Staging a Breakout in 2024
- What is the NASDAQ Stock Exchange?
- Discover the 3 Best-Performing Biotech IPO Stocks of 2024
- Are Penny Stocks a Good Fit for Your Portfolio?
- Hims & Hers: Why This Healthcare Stock’s Growth Makes It a Buy
Receive News & Ratings for Arteris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arteris and related companies with MarketBeat.com's FREE daily email newsletter.